> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vera Therapeutics Records $10.3 Million In Drug Sales — Launch Spending Widens Its Loss
- URL: https://www.bullished.co/vera-therapeutics-records-10-3-million-in-drug-sales-launch-spending-widens-its-loss-055977af/
- Published: 2026-11-06T15:26:37.000Z
- Updated: 2026-11-06T15:26:37.000Z
- Description: TRUTAKNA's rollout brought approximately 700 patient start forms, while Vera seeks full FDA approval based on kidney-function data.
- Author: Matteo Parrino
- Tags: SEC Filings, VERA, Industry: Healthcare

[Vera Therapeutics](https://www.bullished.co/tag/vera/), which develops treatments for autoimmune diseases, recorded $10.3 million in third-quarter sales of kidney drug TRUTAKNA, but launch spending helped widen its net loss to $93.7 million. The company reported the results Thursday alongside an [SEC filing](https://www.sec.gov/Archives/edgar/data/0001831828/000119312526449780/vera-20261105.htm?ref=bullished.co), putting numbers on its transition from drug development to commercial sales.

## Launch Spending Outruns Initial Sales

TRUTAKNA's net product revenue compares with no product sales in the year-earlier quarter. Vera has received approximately 700 patient start forms since launch; those forms are distinct from reported revenue.

Selling, general and administrative expenses reached [$61.4 million](https://www.sec.gov/Archives/edgar/data/0001831828/000119312526449780/vera-ex99%5F1.htm?ref=bullished.co), against $27.5 million a year earlier, as Vera invested in the rollout. The quarterly net loss compares with $80.3 million a year earlier, while the per-share loss increased to $1.30 from $1.26.

Research and development expenses moved in the other direction, falling to $41.3 million from $56.5 million. The main reason was an accounting change tied to commercialization: manufacturing costs for commercial supplies now go into inventory rather than research expenses.

VERA shares fell about 4% to $28.84 in Friday trading.

## Kidney Data Supports Full-Approval Application

TRUTAKNA entered the U.S. market after receiving [accelerated FDA approval](https://www.sec.gov/Archives/edgar/data/0001831828/000119312526449780/vera-ex99%5F1.htm?ref=bullished.co) on July 7, 2026\. Its approved use is to reduce protein in urine in adults with primary immunoglobulin A nephropathy, an autoimmune kidney disease, who are at risk of disease progression.

That approval was based on reduced protein in urine, rather than established long-term slowing of kidney-function decline. Continued approval may depend on a confirmatory trial verifying clinical benefit, the company said.

Vera said its final late-stage trial analysis showed a 76% reduction versus placebo in the risk of a combined measure of kidney disease progression through two years. The drug met every prespecified trial goal. Results were presented at ASN Kidney Week 2026 and published simultaneously in The New England Journal of Medicine.

The annual rate of change in estimated kidney filtration was -0.6 mL/min/1.73m² with TRUTAKNA, versus -5.6 with placebo. Vera used the final analysis to support Tuesday's application for full FDA approval.

TRUTAKNA is a weekly, at-home injection that blocks the immune-signaling molecules BAFF and APRIL. Vera estimates approximately 160,000 people in the U.S. have diagnosed IgA nephropathy, roughly 75% of them commercially insured.

Matt Skelton, Vera Therapeutics' chief commercial officer, said: “Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.”

Vera described the trial's overall safety as generally comparable to placebo. Its prescribing information warns that reduced antibody production can increase infection risk; infections occurred in 32% of treated patients versus 28% receiving placebo, and local administration reactions occurred in 30% versus 5%.

Beyond the approved use, Vera presented interim mid-stage results in adults with IgA nephropathy and primary membranous nephropathy. The company said those findings support further investigation of atacicept in antibody-mediated kidney diseases.

## Cash Use Rises, Borrowing Adds Funds

Operations consumed $305.9 million of cash in the first nine months of 2026, compared with $171.1 million in the same period a year earlier. Vera attributed the increase primarily to launch investment.

Cash, cash equivalents and marketable securities stood at $384.0 million at quarter-end. Vera borrowed $75 million in late October; adjusting solely for that borrowing would put the quarter-end balance at $459 million, rather than representing a new measurement of current cash.

As of Thursday, up to $350 million remained available under Vera's debt facility, conditional on meeting its requirements.

Vera expects potential full FDA approval in mid-2027, subject to review. It also plans to submit a European marketing application in the first quarter of 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Vera Therapeutics, Inc. (VERA)](https://www.sec.gov/Archives/edgar/data/0001831828/000119312526449780/vera-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit vera-ex99\_1.htm — Vera Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001831828/000119312526449780/vera-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Vera outlines goal of 50% covered lives by year-end as it targets full TRUTAKNA approval in mid-2027 (NASDAQ:VERA) | Seeking Alpha](https://seekingalpha.com/news/4667642-vera-outlines-goal-of-50-percent-covered-lives-by-year-end-as-it-targets-full-trutakna?ref=bullished.co) — seekingalpha.com
- [Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference](https://finance.yahoo.com/healthcare/articles/vera-therapeutics-participate-guggenheim-3rd-130000827.html?ref=bullished.co) — Yahoo Finance
- [Vera Therapeutics Provides Business Update and Reports](https://www.globenewswire.com/news-release/2026/11/05/3396989/0/en/vera-therapeutics-provides-business-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com
- [Vera Therapeutics to Participate in the Guggenheim 3rd](https://www.globenewswire.com/news-release/2026/11/02/3393075/0/en/vera-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference.html?ref=bullished.co) — globenewswire.com

### More on Vera Therapeutics

- [Vera Says About Half Of Its $10 Million Launch-Quarter Trutakna Sales Went To Inventory](https://www.bullished.co/vera-says-about-half-of-its-10-million-launch-quarter-trutakna-sales-went-to-inventory-4078ed5a/)

[All Vera Therapeutics (VERA) coverage →](https://www.bullished.co/tag/vera/)